Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
- Rogers, Thomas F;
- Zhao, Fangzhu;
- Huang, Deli;
- Beutler, Nathan;
- Burns, Alison;
- He, Wan-Ting;
- Limbo, Oliver;
- Smith, Chloe;
- Song, Ge;
- Woehl, Jordan;
- Yang, Linlin;
- Abbott, Robert K;
- Callaghan, Sean;
- Garcia, Elijah;
- Hurtado, Jonathan;
- Parren, Mara;
- Peng, Linghang;
- Ricketts, James;
- Ricciardi, Michael J;
- Rawlings, Stephen A;
- Smith, Davey M;
- Nemazee, David;
- Teijaro, John R;
- Voss, James E;
- Andrabi, Raiees;
- Briney, Bryan;
- Landais, Elise;
- Sok, Devin;
- Jardine, Joseph G;
- Burton, Dennis R
- et al.
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263516/Abstract
The development of countermeasures to prevent and treat COVID-19 is a global health priority. In under 7 weeks, we enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate serum and monoclonal antibody responses, adapted our high throughput antibody isolation, production and characterization pipeline to rapidly screen over 1000 antigen-specific antibodies, and established an animal model to test protection. We report multiple highly potent neutralizing antibodies (nAbs) and show that passive transfer of a nAb provides protection against high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.